secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2026-09-08T11:05:06+00:00
Accession:  0001193125-26-384363
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology appoints Jennifer Fulk as CFO and principal accounting officer
----------------------------------------------------------------------------

- Effective Sept 8, 2026, Jennifer Fulk appointed CFO, principal financial and principal accounting officer.
- Fulk replaces Troy E. Wilson as CFO and Thomas Doyle as principal accounting officer.
- Compensation: $550,000 base salary, up to 45% bonus, option for 450,000 shares, PSU for 173,438 shares.
- Prior roles: CFO Soleno Therapeutics, COO/CFO 120Water, CFO Talkspace, 15+ years at Eli Lilly.
- Severance includes 12-18 months salary, COBRA, and equity acceleration in change of control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312526384363/0001193125-26-384363-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312526384363/d458603d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-384363

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer